Anthropic announced Claude Science, an AI tool for scientists, and said it would develop drugs itself targeting neglected diseases—a move that puts it in direct competition with pharmaceutical companies while also selling them software. However, experts stress that AI-designed drugs remain years away from market approval, as the slow, expensive phases of real-world testing and human trials cannot yet be automated or significantly sped up.
Summaries like this, in your inbox every morning.
Sign up free →What happened
Anthropic announced Claude Science, an AI workbench for scientists, at an event this week, and said it would develop drugs of its own, focusing on treatments for "neglected" diseases. The company is actively hiring biologists and building wet labs.
Why it matters
Anthropic is taking a more direct approach to pharma than competitors like OpenAI, Google, and Amazon, which offer life sciences tools but do not develop drugs themselves. This puts Anthropic in the unusual position of selling software to potential drug-development rivals while competing with them as a drugmaker.
What to watch
No AI-designed drug has yet reached the market through clinical trials and FDA approval. Experts say any drug candidate Anthropic develops is likely a decade or more away, since the real-world testing and clinical trials phase is slow and expensive, and many promising candidates fail during human testing.
No comments yet. Be the first to share your thoughts!
Log in to join the discussion
Get curated AI news from 200+ sources delivered daily to your inbox. Free to use.
Get Started FreeFree · takes 30 seconds · unsubscribe anytime
1 minute a day. The AI essentials.
200+ sources · Email / LINE / Slack
